Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Nintedanib (formerly known as BIBF 1120) is an intracellular inhibitor that targets multiple tyrosine kinases. A phase 2 trial suggested that treatment with 150 mg of nintedanib twice daily reduced lung-function decline and acute exacerbations in patients with idiopathic pulmonary fibrosis. METHODS: We conducted two replicate 52-week, randomized, double-blind, phase 3 trials (INPULSIS-1 and INPULSIS-2) to evaluate the efficacy and safety of 150 mg of nintedanib twice daily as compared with placebo in patients with idiopathic pulmonary fibrosis. The primary end point was the annual rate of decline in forced vital capacity (FVC). Key secondary end points were the time to the first acute exacerbation and the change from baseline in the total score on the St. George's Respiratory Questionnaire, both assessed over a 52-week period. RESULTS: A total of 1066 patients were randomly assigned in a 3:2 ratio to receive nintedanib or placebo. The adjusted annual rate of change in FVC was -114.7 ml with nintedanib versus -239.9 ml with placebo (difference, 125.3 ml; 95% confidence interval [CI], 77.7 to 172.8; P<0.001) in INPULSIS-1 and -113.6 ml with nintedanib versus -207.3 ml with placebo (difference, 93.7 ml; 95% CI, 44.8 to 142.7; P<0.001) in INPULSIS-2. In INPULSIS-1, there was no significant difference between the nintedanib and placebo groups in the time to the first acute exacerbation (hazard ratio with nintedanib, 1.15; 95% CI, 0.54 to 2.42; P=0.67); in INPULSIS-2, there was a significant benefit with nintedanib versus placebo (hazard ratio, 0.38; 95% CI, 0.19 to 0.77; P=0.005). The most frequent adverse event in the nintedanib groups was diarrhea, with rates of 61.5% and 18.6% in the nintedanib and placebo groups, respectively, in INPULSIS-1 and 63.2% and 18.3% in the two groups, respectively, in INPULSIS-2. CONCLUSIONS: In patients with idiopathic pulmonary fibrosis, nintedanib reduced the decline in FVC, which is consistent with a slowing of disease progression; nintedanib was frequently associated with diarrhea, which led to discontinuation of the study medication in less than 5% of patients. (Funded by Boehringer Ingelheim; INPULSIS-1 and INPULSIS-2 ClinicalTrials.gov numbers, NCT01335464 and NCT01335477.).
Overview
CoChat Summary
TL;DR
This paper reports two replicate 52-week phase 3 randomized trials showing that nintedanib slowed the decline in forced vital capacity in idiopathic pulmonary fibrosis. Diarrhea was common, but discontinuation due to study medication occurred in less than 5% of patients.
Key findings
- In INPULSIS-1, the adjusted annual rate of change in FVC was -114.7 ml with nintedanib vs -239.9 ml with placebo; the between-group difference was 125.3 ml (95% CI, 77.7 to 172.8; P<0.001).
- In INPULSIS-2, the adjusted annual rate of change in FVC was -113.6 ml with nintedanib vs -207.3 ml with placebo; the between-group difference was 93.7 ml (95% CI, 44.8 to 142.7; P<0.001).
- For time to first acute exacerbation, INPULSIS-1 showed no significant difference (HR 1.15, 95% CI, 0.54 to 2.42; P = 0.67), while INPULSIS-2 showed benefit with nintedanib (HR 0.38, 95% CI, 0.19 to 0.77; P = 0.005).
- The most frequent adverse event was diarrhea: 61.5% vs 18.6% in INPULSIS-1 and 63.2% vs 18.3% in INPULSIS-2 for nintedanib vs placebo, respectively; the conclusion states this led to discontinuation in less than 5% of patients.
Methods
- Two replicate 52-week, randomized, double-blind, phase 3 trials (INPULSIS-1 and INPULSIS-2) compared nintedanib 150 mg twice daily with placebo in patients with idiopathic pulmonary fibrosis.
- 1066 patients were randomly assigned in a 3:2 ratio to nintedanib or placebo.
- Primary outcome was the annual rate of decline in forced vital capacity (FVC); key secondary outcomes were time to first acute exacerbation and change in St. George’s Respiratory Questionnaire total score over 52 weeks.
Limitations
- The text does not state formal study limitations.
- Evident from the paper’s own reporting: the effect on acute exacerbation was inconsistent across the two replicate trials (no significant difference in INPULSIS-1, significant benefit in INPULSIS-2).
- Evident from the text: the provided excerpt does not report the full results for the St. George’s Respiratory Questionnaire outcome, so that secondary endpoint cannot be fully summarized from this text alone.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 Valid · 1 Not valid · 0 Not checked · 11 Own results and interpretations
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“which led to discontinuation of the study medication in less than 5% of patients.”
states a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: unclear — It is unclear why the paper says it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“in INPULSIS-2, there was a significant benefit with nintedanib versus placebo (hazard ratio, 0.38; 95% CI, 0.19 to 0.77; P = 0.005).”
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and -113.6 ml with nintedanib versus -207.3 ml with placebo (difference, 93.7 ml; 95% CI, 44.8 to 142.7; P<0.001) in INPULSIS-2.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and 63.2% and 18.3% in the two groups, respectively, in INPULSIS-2.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The adjusted annual rate of change in FVC was -114.7 ml with nintedanib versus -239.9 ml with placebo (difference, 125.3 ml; 95% confidence interval [CI], 77.7 to 172.8; P<0.001) in INPULSIS-1”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
5 more claims
Create a free account to see all 12 claims and every source verdict.
- It may state two separate claims as one. 1
- Probably not a substantial claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Idiopathic pulmonary fibrosis (IPF), the prototype of fibrotic ILDs, carries a prognosis of 3–5 years survival after diagnosis when untreated. Two anti-fibrotic medications (nintedanib and pirfenidone) have been shown to reduce the rate of forced vital capacity (FVC) decline and slow disease progression in patients with a definite usual interstitial pneumonia (UIP) pattern and with a probable UIP pattern on high resolution CT (HRCT).(191–193)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [192]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, both have significant adverse effects and neither completely arrest the decline in lung function.”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Reported adverse events in the present trial were generally acceptable and largely consistent with events previously reported by participants in the placebo arms of randomized controlled trials in IPF [45,46].”
From Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study (2019) · cites this paper as [46]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“nintedanib, which was originally developed with oncology in mind, for treatment of idiopathic pulmonary fibrosis150.”
From A framework for advancing our understanding of cancer-associated fibroblasts (2020) · cites this paper as [150]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinical trials investigating these two drugs in patients with IPF have demonstrated only a slowing of disease progression33,34, as measured by forced vital capacity (FVC) and self-reported quality of life (QOL) metrics, and unclear benefit to survival26, making the development of therapies that can restore lung function and reverse the course of disease a priority.”
From A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial (2025) · cites this paper as [34]
Experimental — accuracy not yet measured
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Self-citationThe St George's Respiratory Questionnaire
Jones, P. W., Quirk, F. H., & Baveystock, C. M. (1991) · Respiratory Medicine · doi:10.1016/s0954-6111(06)80166-6 · Cited by 2,683
King, T. E., Pardo, A., & Selman, M. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60052-4 · Cited by 2,194
Self-citationEfficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
Richeldi, L., Costabel, U., Selman, M., Kim, D. S., Hansell, D. M., Nicholson, A. G., Brown, K. K., Flaherty, K. R., Noble, P. W., Raghu, G., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103690 · Cited by 1,157
Self-citationAcute Exacerbations of Idiopathic Pulmonary Fibrosis
Collard, H. R., Moore, B. B., Flaherty, K. R., Brown, K. K., Kaner, R. J., King, T. E., Lasky, J. A., Loyd, J. E., Noth, I., Olman, M. A., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200703-463pp · Cited by 1,130
Self-citationBIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy
Hilberg, F., Roth, G. J., Krssak, M., Kautschitsch, S., Sommergruber, W., Tontsch-Grunt, U., Garin-Chesa, P., Bader, G., Zoephel, A., Quant, J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6307 · Cited by 1,056
St. George's Respiratory Questionnaire: MCID
Jones, P. W. (2005) · COPD: Journal of Chronic Obstructive Pulmonary Disease · doi:10.1081/copd-200050513 · Cited by 855
Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome
Song, J. W., Hong, S.-B., Lim, C.-M., Koh, Y., & Kim, D. S. (2011) · European Respiratory Journal · doi:10.1183/09031936.00159709 · Cited by 783
Self-citationChanges in Clinical and Physiologic Variables Predict Survival in Idiopathic Pulmonary Fibrosis
Collard, H. R., King, T. E., Bartelson, B. B., Vourlekis, J. S., Schwarz, M. I., & Brown, K. K. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200211-1311oc · Cited by 764
Self-citation
Cited by
Items 1,901–2,000 of 4,628
Shen, L., Lei, S., Huang, L., Li, S., Yi, S., Breitzig, M., Huang, M., Mo, X., Sun, H., Zheng, Q. Y., et al. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.03.001 · Cited by 15
Daoussis, D., & Liossis, S. C. (2019) · Mediterranean Journal of Rheumatology · doi:10.31138/mjr.30.1.33 · Cited by 18
Sleep and interstitial lung disease
Myall, K. J., West, A., & Kent, B. D. (2019) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000620 · Cited by 16
“We now have pharmacological interventions, pirfenidone and nintedanib, which slow the progression of disease in IPF, and are being trialed in other fibrotic interstitial lung diseases (fILD) [2,3].”
BackgroundThe efficacy of pirfenidone in a sheep model of pulmonary fibrosis
Dewage, S. N. V., Organ, L. A., Koumoundouros, E., Derseh, H. B., Perera, K. U. E., Samuel, C. S., Stent, A. W., & Snibson, K. J. (2019) · Experimental Lung Research · doi:10.1080/01902148.2019.1695019 · Cited by 14
“Successful clinical trials for both nintedanib(6,7) and pirfenidone(8) have now allowed these drugs to be important treatment options for the disease.(9,10) However, as these treatments only slow the progression of the disease and often have several side-effects, they are not considered effective cures for this ailmen…”
BackgroundEasthausen, I. J., Podolanczuk, A. J., Hoffman, E. A., Kawut, S. M., Oelsner, E. C., Kim, J. S., Raghu, G., Stukovsky, K. H., Redline, S. S., McClelland, R. L., et al. (2020) · Respirology · doi:10.1111/resp.13783 · Cited by 17
Self-citationCardiovascular implications of idiopathic pulmonary fibrosis: A way forward together?
Mosher, C. L., & Mentz, R. J. (2020) · American Heart Journal · doi:10.1016/j.ahj.2020.04.027 · Cited by 16
Shedding light on developmental drugs for idiopathic pulmonary fibrosis
Spagnolo, P., Bonella, F., Ryerson, C. J., Τzouvelekis, Α., & Maher, T. M. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1782885 · Cited by 17
A novel tree shrew model of pulmonary fibrosis
Che, P., Wang, M., Larson‐Casey, J. L., Hu, R.-H., Cheng, Y., Hamdaoui, M. E., Zhao, X., Grytz, R., Carter, A. B., & Ding, Q. (2020) · Laboratory Investigation · doi:10.1038/s41374-020-00476-3 · Cited by 19
Balestro, E., Castelli, G., Bernardinello, N., Cocconcelli, E., Biondini, D., Fracasso, F., Rea, F., Saetta, M. P., Baraldo, S., & Spagnolo, P. (2020) · Chronic Respiratory Disease · doi:10.1177/1479973120958428 · Cited by 15
“Antifibrotic treatment (i.e., pirfenidone and nintedanib) slow down functional decline and disease progression of patients with IPF.7,8 In our study, nearly half of patients (48”
BackgroundInfluentialConca, W., Weheba, I., Abouzied, M., Abdelsayed, A., Aleyouni, Y., Mutairy, E. A., Bakshi, N., & Khalid, M. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.585761 · Cited by 16
“With regard to the fibrotic component of RPILD, pirfenidone delays the progression of lung fibrosis (Li et al., 2016), and nintedanib, an anti-fibrotic tyrosine kinase inhibitor, decreases the rate of decline in forced vital capacity (FVC) in various ILDs (Richeldi et al., 2014; Wollin et al., 2015; Distler et al., 20…”
BackgroundPastré, J., Barnett, S. D., Ksovreli, I., Taylor, J., Brown, A. W., Shlobin, O. A., Ahmad, K., Khangoora, V. S., Aryal, S., King, C. S., et al. (2021) · Respiratory Research · doi:10.1186/s12931-020-01600-z · Cited by 19
Hu, N., Mackey, H. M., & Thomas, R. G. (2021) · Biometrical Journal · doi:10.1002/bimj.202000184 · Cited by 17
Goos, T., Sadeleer, L. D., Yserbyt, J., Verleden, G. M., Vermant, M., Verleden, S. E., & Wuyts, W. A. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10061330 · Cited by 17
Komatsu, M., Yamamoto, H., Kitaguchi, Y., Kawakami, S., Matsushita, M., Uehara, T., Kinjo, T., Wada, Y., Ichiyama, T., Urushihata, K., et al. (2021) · Medicine · doi:10.1097/md.0000000000025322 · Cited by 20
Rahaghi, F., Belperio, J. A., Fitzgerald, J., Gulati, M., Hallowell, R. W., Highland, K. B., Huie, T. J., Kim, G. H. J., Kolb, M. R. J., Lasky, J. A., et al. (2021) · Clinical Medicine Insights Circulatory Respiratory and Pulmonary Medicine · doi:10.1177/11795484211006050 · Cited by 18
Self-citationVirk, H. S., Biddle, M., Smallwood, D. T., Weston, C. A., Castells, E., Bowman, V. W., McCarthy, J., Amrani, Y., Duffy, S. M., Bradding, P., et al. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15467 · Cited by 17
Okumura, M., Hojo, H., Nakamura, M., et al. (2021) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2021.05.026 · Cited by 16
Wang, D., Lu, C. Y., Li, J., Deng, B., Yan, T., Xin, Y., Zhang, J., Zhang, B., & Xie, J. (2021) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2021.106009 · Cited by 17
Jessen, H., Hoyer, N., Prior, T. S., Frederiksen, P., Rønnow, S. R., Karsdal, M. A., Leeming, D. J., Bendstrup, E. M., Sand, J. M. B., & Shaker, S. B. (2021) · BMC Pulmonary Medicine · doi:10.1186/s12890-021-01684-3 · Cited by 20
Mooney, J. J., Reddy, S. R., Chang, E. Y., Broder, M. S., Gokhale, S., & Corral, M. (2021) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2021.27.12.1724 · Cited by 19
García-Fernández, F., Marchena‐Gómez, J., Morán, V. C., Hermida, M. I. G., Sotgiu, E., & Pérez, G. V. (2011) · PubMed · Cited by 14
Pemafibrate Attenuates Pulmonary Fibrosis by Inhibiting Myofibroblast Differentiation
Liu, Y., Chen, S., Yu, L., Deng, Y., Li, D., Yu, X., Chen, D., Lu, Y., Liu, S., & Chen, R. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.108728 · Cited by 20
Pharmacological Activities of Mogrol: Potential Phytochemical against Different Diseases
Jaiswal, V. K., & Lee, H. (2023) · Life · doi:10.3390/life13020555 · Cited by 16
“Mogrol treatment significantly reduced weight loss and pulmonary index compared to the bleomycin group at both doses (5 or 10 mg/kg), similar to the antifibrotic effects of the nintedanib (a positive drug at a dose of 40 mg/kg) group [26,45].”
The Future of Clinical Trials in Idiopathic Pulmonary Fibrosis
Podolanczuk, A. J., Richeldi, L., & Martínez, F. J. (2023) · JAMA · doi:10.1001/jama.2022.23955 · Cited by 17
Self-citationPlantier, L., Debray, M., Estellat, C., Flamant, M., Roy, C., Bancal, C., Borie, R., Israël‐Biet, D., Mal, H., Crestani, B., et al. (2016) · Journal of Breath Research · doi:10.1088/1752-7155/10/1/016005 · Cited by 18
The effect of mTOR inhibitors on respiratory infections in lymphangioleiomyomatosis
Courtwright, A., Goldberg, H. J., Henske, E. P., & El‐Chemaly, S. (2017) · European Respiratory Review · doi:10.1183/16000617.0004-2016 · Cited by 16
Pulmonary fibrosis, part II: state-of-the-art patient management
Meyer, K. C. (2017) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2017.1312347 · Cited by 17
Ilomastat, a synthetic inhibitor of MMPs, prevents lung injury induced by γ-ray irradiation in mice
Li, X., Ma, D., Zha, X., Quan, D., Pan, D., Sun, M., Hu, B., & Zhao, B. (2017) · Oncotarget · doi:10.18632/oncotarget.18487 · Cited by 16
Scleroderma-related interstitial lung disease
Suliman, S. A., Harash, A. A., Roberts, W. N., Perez, R. L., & Roman, J. (2017) · Respiratory Medicine Case Reports · doi:10.1016/j.rmcr.2017.07.007 · Cited by 23
Dellaripa, P. F. (2017) · Clinical Immunology · doi:10.1016/j.clim.2017.09.015 · Cited by 16
Zhang, Y., Xin, Q., Wu, Z. S., Wang, C., Wang, Y., Wu, Q., & Niu, R. L. (2018) · Medical Science Monitor · doi:10.12659/msm.908702 · Cited by 17
Elicker, B. M., Kallianos, K. G., Jones, K. D., & Henry, T. S. (2018) · Seminars in Ultrasound CT and MRI · doi:10.1053/j.sult.2018.11.010 · Cited by 18
Segurança e tolerabilidade de Nintedanibe em pacientes com fibrose pulmonar idiopática no Brasil
Pereira, C. A. D. C., Martínez, J. A. B., Baldi, B. G., Jezler, S. F. D. O., Rubin, A. S., Rufino, R., Zonzin, G., Quaresma, M., Trampisch, M., & Rabahi, M. F. (2019) · Jornal Brasileiro de Pneumologia · doi:10.1590/1806-3713/e20180414 · Cited by 25
Xia, Y., Bao, H., Huang, J., Li, X., Yu, C., Zhang, Z., & Wang, H. (2020) · Biomaterials Science · doi:10.1039/d0bm00063a · Cited by 16
Dy, G. K., Prasad, D., Kumar, P. K. M., Attwood, K. M., & Adjei, A. A. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.11.019 · Cited by 22
Transbronchial cryobiopsy in diffuse parenchymal lung disease. A new star in the horizon.
Poletti, V. E., & Benzaquen, S. (2014) · Sarcoidosis vasculitis and diffuse lung diseases · Cited by 16
Dinnon, K. H., Leist, S. R., Okuda, K., Dang, H., Fritch, E. J., Gully, K. L., la Cruz, G. D., Evangelista, M. D., Asakura, T., Gilmore, R. C., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.02.15.480515 · Cited by 16
Park, M. Y., Bae, S., Heo, J. A., Park, M., Kim, Y., Han, J., Jang, I., Yu, K., & Oh, J. (2023) · Clinical and Translational Science · doi:10.1111/cts.13518 · Cited by 15
Fibrosis‐on‐Chip: A Guide to Recapitulate the Essential Features of Fibrotic Disease
Streutker, E. M., Devamoglu, U., Vonk, M. C., Verdurmen, W. P. R., & Gac, S. L. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202303991 · Cited by 18
Unlocking the potential of tranilast: Targeting fibrotic signaling pathways for therapeutic benefit
Massoud, G., Parish, M. A., Hazimeh, D., Moukarzel, P., Singh, B., Vaught, K. C. C., Segars, J., & Islam, M. S. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112423 · Cited by 17
3D printed drug-eluting stents: Toward personalized therapy for airway stenosis
Krivitsky, A., Paunović, N., Klein, K., Coulter, F. B., Schleich, S., Karol, A. A., Bauer, A., Krivitsky, V., Lohmann, V., Carril, P. C., et al. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.11.031 · Cited by 18
Lu, J., Wang, Z., & Zhang, L. (2025) · Gene · doi:10.1016/j.gene.2025.149271 · Cited by 21
Pezet, M. G., Torres, J. A., Thimraj, T. A., Matković, I., Schrode, N., Murray, J. W., Saqi, A., Beaumont, K. G., & Snoeck, H. (2025) · Nature Biotechnology · doi:10.1038/s41587-025-02569-0 · Cited by 30
Investigational drugs for idiopathic pulmonary fibrosis
Varone, F., Montemurro, G., Macagno, F., Calvello, M., Conte, E. G., Intini, E., Iovene, B., Leone, P. M., Mari, P., & Richeldi, L. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1364361 · Cited by 15
Self-citationPovitz, M., Li, L., Hosein, K., Shariff, S. Z., & Mura, M. (2019) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2019.03.012 · Cited by 15
Yamazaki, R., Nishiyama, O., Saeki, S., Sano, H., Iwanaga, T., & Tohda, Y. (2021) · Scientific Reports · doi:10.1038/s41598-021-85234-1 · Cited by 15
Updates in Systemic Sclerosis Treatment and Applicability to Pediatric Scleroderma
Torok, K. S. (2021) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2021.07.004 · Cited by 17
SHP2 : The protein tyrosine phosphatase involved in chronic pulmonary inflammation and fibrosis
Chang, C., Lin, C., Chen, B.-C., Lin, P., & Chen, C. (2021) · IUBMB Life · doi:10.1002/iub.2559 · Cited by 18
The experience of people with idiopathic pulmonary fibrosis living through the COVID‐19 pandemic
Ryan, N., & Meskell, P. (2022) · Journal of Advanced Nursing · doi:10.1111/jan.15187 · Cited by 16
Treating Pulmonary Fibrosis with Non-Viral Gene Therapy: From Bench to Bedside
Huang, T., Gao, J. L., Cai, L., Xie, H., Wang, Y., Wang, Y., & Zhou, Q. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14040813 · Cited by 15
BMP3b is a Novel Antifibrotic Molecule Regulated by Meflin in Lung Fibroblasts
Suzuki, A., Sakamoto, K., Nakahara, Y., Enomoto, A., Hino, J., Ando, A., Inoue, M., Shiraki, Y., Omote, N., Kusaka, M., et al. (2022) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2021-0484oc · Cited by 18
COVID-19 and fibrosis: Mechanisms, clinical relevance, and future perspectives
Saifi, M. A., Bansod, S., & Godugu, C. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.103345 · Cited by 16
Lian, X., Ye, Y., Zou, J., Wu, C., Ye, S., Guo, Q., Chen, S., Lu, L., Wang, R., Fu, Q., et al. (2022) · Rheumatology · doi:10.1093/rheumatology/keac525 · Cited by 16
High-Resolution Computed Tomography of Fibrotic Interstitial Lung Disease
Rodriguez, K. J., Ashby‐Padial, C., Rullán-Varela, V., & Sharma, A. (2022) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0042-1755563 · Cited by 18
Chen, H., Luo, Y., Zhu, Y., Ye, Y., Chen, D., Song, X., Xiao, Z., Liu, M., & Li, S. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1070736 · Cited by 17
“Although pirfenidone and nintedanib can improve lung function and exercise tolerance to some extent, it is still difficult to prevent IPF from progressing (King Jr et al., 2014; Richeldi et al., 2014).”
BackgroundSgalla, G., Simonetti, J., Cortese, S., & Richeldi, L. (2023) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2023.2173061 · Cited by 19
Self-citationIdentification and validation of chemokine system-related genes in idiopathic pulmonary fibrosis
Zhao, T., Wu, X., Zhao, X., Yao, K., Li, X., & Ni, J. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1159856 · Cited by 15
“Pirfenidone and nintedanib are currently FDAapproved oral agents that reduce IPF progression (4, 5).”
BackgroundAn update on current and emerging drug treatments for idiopathic pulmonary fibrosis
Trachalaki, A., Sultana, N., & Wells, A. U. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2213436 · Cited by 15
Idiopathic pulmonary fibrosis: current diagnosis and treatment
Amaral, A. F., Colares, P. D. F. B., & Kairalla, R. A. (2023) · Jornal Brasileiro de Pneumologia · doi:10.36416/1806-3756/e20230085 · Cited by 32
A role for the terminal C5-C9 complement pathway in idiopathic pulmonary fibrosis
Sikkeland, L. I. B., Ueland, T., Lund, M. B., Durheim, M. T., & Mollnes, T. E. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1236495 · Cited by 19
“Although anti-fibrotic therapies approved for IPF improve respiratory outcomes (2, 3), these drugs are associated with substantial side effects, and do not cure the disease.”
BackgroundDomvri, K., Organtzis, I., Apostolopoulos, A. L., Fouka, E., Kontakiotis, T., & Papakosta, D. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13091307 · Cited by 16
Hadi, D. D., Marsool, M. D. M., Marsool, A. D. M., Vora, N., Al‐Badri, S. G., Al‐Fatlawi, N., Wssawi, A. F. A. A., Al‐Ibraheem, A. M. T., Hamza, K. A., Prajjwal, P., et al. (2023) · Immunity Inflammation and Disease · doi:10.1002/iid3.1079 · Cited by 16
Ishikawa, T., Nishikiori, H., Mori, Y., Fujino, K., Saito, A., Takahashi, M., Kuronuma, K., Hinotsu, S., & Chiba, H. (2024) · BMC Pulmonary Medicine · doi:10.1186/s12890-023-02776-y · Cited by 17
Aguilar, P. M., Gómez-Carrera, L., Bonilla, G., Díaz‐Almirón, M., Gayá, F., Carpio, C., Zamarrón, E., Peña, M. F.-V., Torres, I., Esteban, I., et al. (2024) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1331134 · Cited by 20
Selenite selectively kills lung fibroblasts to treat bleomycin-induced pulmonary fibrosis
Lin, J.-H., Liu, C., Liu, C., Hsu, T.-W., Yeh, Y., How, C., Hsu, H., & Hung, S. (2024) · Redox Biology · doi:10.1016/j.redox.2024.103148 · Cited by 15
“Although two antifibrotic agents are available for IPF [3,4], their efficacy is limited and the cost is relatively high.”
BackgroundYamakawa, H., Sato, S., Ohta, H., Kusano, K., Kawabe, R., Oba, T., Uzuka, C., Sasaki, H., Akasaka, K., Amano, M., et al. (2024) · Respiratory Investigation · doi:10.1016/j.resinv.2024.04.011 · Cited by 18
Ortíz, A. D. R., Jiménez-Rodríguez, B. M., Ramírez, C. L., López-Bauzá, Á., Perez-Morales, M. D., Delgado-Torralbo, J. A., Moral, C. V., & Navarrete, B. A. (2024) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2023-001687 · Cited by 26
Maddali, M. V., Moore, A. R., Sinha, P., Newton, C. A., Kim, J. S., Adegunsoye, A., Ma, S., Strek, M. E., Chen, C., Linderholm, A., et al. (2024) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202402-0339oc · Cited by 18
Evidence from recent clinical trials in fibrotic interstitial lung diseases
Cottin, V., & Valenzuela, C. (2024) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000001089 · Cited by 18
Self-citationLRG1-Targeted Nintedanib Delivery for Enhanced Renal Fibrosis Mitigation
Zhang, Y., Wang, L., Yang, X. J., Fan, L., Li, Y., Zhu, F., Zhu, A., Du, S., Min, H., & Qi, Y. (2024) · Nano Letters · doi:10.1021/acs.nanolett.4c03315 · Cited by 16
Han, X., Zhang, A., Meng, Z., Wang, Q., Liu, S., Wang, Y., Tan, J., Guo, L., & Li, F. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e38173 · Cited by 18
“Tyrosine kinase inhibitors, such as pirfenidone and nintedanib, which have received FDA approval, are being utilized as first-line treatments for IPF [6].”
BackgroundOpen-Access Biorepository for Idiopathic Pulmonary Fibrosis. The Way Forward
White, E. S., Brown, K. M., Collard, H. R., Conoscenti, C., Cosgrove, G. P., Flaherty, K. R., Leff, J. A., Martínez, F. J., Roman, J., Rose, D., et al. (2014) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201406-289oi · Cited by 15
Self-citationThe INPULSIS enigma: exacerbations in idiopathic pulmonary fibrosis
Suissa, S., & Ernst, P. (2014) · Thorax · doi:10.1136/thoraxjnl-2014-206598 · Cited by 15
Impact of angiopoietin-1 and -2 on clinical course of idiopathic pulmonary fibrosis
Uehara, M., Enomoto, N., Mikamo, M., Oyama, Y., Kono, M., Fujisawa, T., Inui, N., Nakamura, Y., & Suda, T. (2016) · Respiratory Medicine · doi:10.1016/j.rmed.2016.03.001 · Cited by 17
“VEGF and FGF increase the Ang-2 concentration in endothelial cells [30]; therefore, nintedanib, which is an intracellular inhibitor of multiple tyrosine kinases such as VEGF and FGF receptors [36], may be effective for the suppression of Ang-2 in patients with IPF.”
BackgroundKulkarni, T., Willoughby, J., Lara, M. D. P. A., et al. (2016) · Respiratory Medicine · doi:10.1016/j.rmed.2016.04.010 · Cited by 15
Toll-like receptors and autophagy in interstitial lung diseases
Margaritopoulos, G. A., Lasithiotaki, I., & Antoniou, K. M. (2016) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2016.09.032 · Cited by 17
Schliemann, C., Gerß, J., Wiebe, S., Mikesch, J., Knoblauch, N. T. M., Sauer, T., Angenendt, L., Kewitz, T., Urban, M., Butterfaß‐Bahloul, T., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0164499 · Cited by 17
Chan, P., Bax, L., Chen, C., Zhang, N., Huang, S., Soares, H. D., Rosen, G., & Abutarif, M. A. (2017) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12227 · Cited by 16
Clinical experience in idiopathic pulmonary fibrosis: a retrospective study
Guiot, J., Duysinx, B., Seidel, L., Henket, M. A., Gester, F., Bonhomme, O., Corhay, J.-L., & Louis, R. E. (2017) · Acta Clinica Belgica · doi:10.1080/17843286.2017.1399228 · Cited by 18
Kondoh, Y., Taniguchi, H., Kataoka, K., Furukawa, T., Shintani, A., Fujisawa, T., Suda, T., Arita, M., Baba, T., Ichikado, K., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0193608 · Cited by 15
Self-citationBlandinières, A., Gille, T., Sadoine, J., Bièche, I., Slimani, L., Dizier, B., Gaussem, P., Chaussain, C., Planès, C., Dorfmüller, P., et al. (2018) · Stem Cell Reviews and Reports · doi:10.1007/s12015-018-9846-5 · Cited by 15
Khan, F., Stewart, I. D., Howard, L., McKeever, T. M., Jones, S., Hearson, G., Braybrooke, R., Edwards, C. C., Jenkins, G. R., & Saini, G. (2019) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2019-000439 · Cited by 17
Raupp, D., Fernandes, R. S., Antunes, K. H., Perin, F. A., & Rigatto, K. (2020) · Peptides · doi:10.1016/j.peptides.2020.170384 · Cited by 15
Sgalla, G., Larici, A. R., Golfi, N., Calvello, M., Farchione, A., del Ciello, A., Varone, F., Iovene, B., Manfredi, R. M., & Richeldi, L. (2020) · BMC Pulmonary Medicine · doi:10.1186/s12890-020-01289-2 · Cited by 19
Self-citationAmlani, B., Elsayed, G., Barvalia, U., et al. (2020) · Sarcoidosis vasculitis and diffuse lung diseases · doi:10.36141/svdld.v37i2.8461 · Cited by 15
Treatment of Idiopathic Pulmonary Fibrosis
Abuserewa, S. T. H., Duff, R., & Becker, G. (2021) · Cureus · doi:10.7759/cureus.15360 · Cited by 18
“Clinical trials TOMORROW trial [27,28], INPULSIS-1, and INPULSIS-2 trials [16,29-31] ASCEND trial [32], CAPACITY 004, and 006 trials [33]”
BackgroundMatsuo, S., Okamoto, M., Ikeuchi, T., Zaizen, Y., Inomoto, A., Haraguchi, R., Mori, S., Sasaki, R., Nouno, T., Tanaka, T., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10143153 · Cited by 18
Myeloperoxidase and associated lung disease: Review of the latest developments
Hu, H., & Keat, K. (2021) · International Journal of Rheumatic Diseases · doi:10.1111/1756-185x.14213 · Cited by 15
The Development of 3-substituted Indolin-2-one Derivatives as Kinase Inhibitors for Cancer Therapy
Xu, C., Liu, Y., & Zhao, G. (2021) · Current Medicinal Chemistry · doi:10.2174/0929867328666210831142311 · Cited by 16
The Design of Multi-target Drugs to Treat Cardiovascular Diseases: Two (or more) Birds on One Stone
Caruso, L., Nadur, N. F., da Fonseca, M. B., Ferreira, L. A., Lacerda, R. B., Graebin, C. S., & Kümmerle, A. E. (2022) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026622666220201151248 · Cited by 18
Identification of targetable kinases in idiopathic pulmonary fibrosis
Higo, H., Ohashi, K., Tomida, S., Okawa, S., Yamamoto, H., Sugimoto, S., Senoo, S., Makimoto, G., Ninomiya, K., Nakasuka, T., et al. (2022) · Respiratory Research · doi:10.1186/s12931-022-01940-y · Cited by 20
Impact of Palliative Care in End-of-Life of Fibrotic Interstitial Lung Disease Patients
Chai, G. T., Neo, H. Y., Abisheganaden, J. A., & Hum, A. Y. M. (2022) · American Journal of Hospice and Palliative Medicine® · doi:10.1177/10499091221083575 · Cited by 19
The Association between Exposures and Disease Characteristics in Familial Pulmonary Fibrosis
Copeland, C. R., Donnelly, E. F., Mehrad, M., Ding, G., Markin, C. R., Douglas, K., Wu, P., Cogan, J. D., Young, L. R., Bartholmai, B. J., et al. (2022) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202203-267oc · Cited by 15
Self-citationZhou, C., Yang, Y., Lin, X., Fang, N., Chen, L., Jiang, J., Deng, H., Deng, Y., Wan, M., Qiu, G., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.935779 · Cited by 19
“Although there is no effective treatment to reverse fibrosis, nintedanib and pirfenidone can help to retard its progression (41, 42).”
BackgroundChen, C., Tung, H.-Y., Tseng, Y., Huang, J., Shi, L.-S., & Ye, Y. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120950 · Cited by 18
Pharmacological Activities of Ginkgolic Acids in Relation to Autophagy
Ding, Y. F., Ding, Z., Xu, J., Li, Y., & Chen, M. (2022) · Pharmaceuticals · doi:10.3390/ph15121469 · Cited by 16
New Therapeutic Avenues for Treatment of Fibrosis: Can We Learn from Other Diseases?
Rogler, G. (2014) · Digestive Diseases · doi:10.1159/000367825 · Cited by 15
Management of Connective Tissue Disease–associated Interstitial Lung Disease
Chartrand, S., & Fischer, A. (2015) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2015.01.002 · Cited by 16
Novel Treatments for Idiopathic Pulmonary Fibrosis
Spagnolo, P. (2015) · The American Journal of Medicine · doi:10.1016/j.amjmed.2015.01.003 · Cited by 12
Heinzelmann, K., Noskovičová, N., Merl‐Pham, J., Preißler, G., Winter, H., Lindner, M., Hatz, R. A., Hauck, S. M., Behr, J., & Eickelberg, O. (2016) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2016.02.013 · Cited by 20
Metadata
- Authors
- Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., Kim, D. S., Kolb, M., Nicholson, A. G., Noble, P. W., Selman, M., Taniguchi, H., Brun, M., Le Maulf, F., Girard, M., Stowasser, S., Schlenker-Herceg, R., Disse, B., & Collard, H. R.
- Affiliations
- NIHR Southampton Respiratory Biomedical Research Unit (GB)
- University of Washington (US)
- Nippon Medical School (JP)
- Ruhrlandklinik (DE)
- Université de Lyon (FR)
- Michigan Medicine (US)
- Royal Brompton & Harefield NHS Foundation Trust (GB)
- NHO Kinki Chuo Chest Medical Center (JP)
- Asan Medical Center (KR)
- McMaster University (CA)
- Cedars-Sinai Medical Center (US)
- Instituto Nacional de Enfermedades Respiratorias (MX)
- Tosei General Hospital (JP)
- Boehringer Ingelheim (Germany) (DE)
- University of California, San Francisco (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-05-29
- Volume
- 370
- Issue
- 22
- Pages
- 2071-2082
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2138871107
- Cited by
- 4,654
- References
- 21
- Citations by year
- 2026: 338 · 2025: 372 · 2024: 479 · 2023: 412 · 2022: 429 · 2021: 501 · 2020: 423 · 2019: 350 · 2018: 345 · 2017: 328 · 2016: 293 · 2015: 292 · 2014: 74
- FWCI
- 263.74
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Use Siena air (University of Siena) (submittedVersion, cc-by-nc-nd)
- Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Digital Access to Libraries (submittedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Funders
- Amgen
- Pfizer
- GlaxoSmithKline
- Sanofi
- Gilead Sciences
- Biogen
- Celgene
- FibroGen
- Ikaria
- University Hospital Southampton NHS Foundation Trust
- Massachusetts Medical Society
- Royal Brompton and Harefield NHS Foundation Trust
- Galecto
- Veracyte
- National Institute for Health and Care Research (NF-SI-0512-10157)
- Imperial College London
- Shionogi
- Genentech
- Japan Society for the Promotion of Science (24591149)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- nintedanib, idiopathic pulmonary fibrosis, tyrosine kinase inhibitors, forced vital capacity decline, acute exacerbation, St George's Respiratory Questionnaire, drug safety, INPULSIS trials, lung function preservation, adverse events, diarrhea, liver enzymes, proteinuria, thrombocytopenia, neutropenia, antifibrotic therapy
- MeSH terms
- Aged, Double-Blind Method, Enzyme Inhibitors, Female, Humans, Indoles, Male, Middle Aged, Protein-Tyrosine Kinases, Quality of Life, Vital Capacity, Treatment Outcome, Disease Progression, Protein Kinase Inhibitors, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.